The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of ...

Keytruda is an immunotherapy drug that is used to treat different types of cancers. The drug helps the body's own immune system to fight the cancer cells. Developed and sold by Merck & Co., the drug ...

Keytruda is an immunotherapy drug approved for multiple cancer types since 2014 It activates the immune system by blocking PD-1 to help T-cells attack cancer cells The drug is prescribed based on ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, cervical cancer, renal cell cancer and aggressive breast cancer, among others.

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...

The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.